All three enzymes have been reported to play a role in chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL)10, and a pan-AKR1C inhibitor outperformed the AKR1C3 selective inhibitor medroxyprogesterone acetate in reducing cell viability in several acute myeloid leukemia (AML) cell lines. This evidence concerns the gene AKR1C3 and acute myeloid leukemia.